Global mRNA Technology Market: Investment & Growth Opportunity Analysis, 2020-2030
$3,150.00 – $5,720.00
Increasing investments and R&D activities in mRNA-based technologies are fueling the market growth
The global mRNA technology market is expected to exhibit a marginal growth rate of 1.8% during the forecast period of 2022-2030. One of the major factors driving the market growth is the increased prevalence of medical disorders such as diabetes, tuberculosis (TB), cancer, and cardiovascular diseases (CVDs). The industry is also benefiting from the rising demand for therapeutic drugs and vaccines for COVID-19, Ebola, influenza, infectious and chronic diseases such as HIV, and other viral illnesses.
The recent COVID-19 outbreak has been a launching year for the mRNA technology platforms with the extensive use of mRNA vaccines for treating COVID-19. The market has observed skyrocketed sales of COVID-19 mRNA vaccines during 2020 and 2021. Moreover, the fact that mRNA vaccines hold much more potential than current prophylactic COVID-19 vaccines coupled with the soaring investments in the development of mRNA-based technologies and the perception that COVID-19 will continue to affect the global population, the market for mRNA technologies is expected to witness a steady decline in the few upcoming years.
However, with the commercial launch of a few mRNA products, the market is likely to observe a significant push at the end of the forecast period. Pharmaceutical companies are investing in mRNA technology as it allows them to mix numerous molecules into a therapeutic drug, technological advancements, extensive biotechnology research and development (R&D) efforts and advancements in healthcare technologies are some factors responsible for market expansion.
For instance, in June 2022, Pfizer Inc. announced to further strengthen its commitment to US manufacturing with a US$ 120 million investment at its Kalamazoo, Michigan, facility, enabling US-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The investment will expand the production of active pharmaceutical ingredients (API) and registered starting materials (RSMs) used in the manufacture of nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer’s laboratories.
The oncology segment holds a prominent share in the global mRNA technology market
The rise in the prevalence of cancer is expected to provide significant growth opportunities for the market during the forecast period. For instance, according to the World Health Organization (WHO), cancer is one of the leading causes of mortalities globally which accounted for around 10 million mortalities in 2020. Cancer-causing infections such as hepatitis and human papillomavirus are responsible for 30% of cancer cases in low and lower-middle-income countries. Moreover in 2021, according to the National Center for Health Statistics, 1,896,180 new cases cancer cases and 608,570 cancer mortalities were recorded in the US.
Owing to the increased number of cases, companies have been collaborating in an effort to provide better treatment to patients. For instance, in October 2017, Eli Lilly and Company and CureVac AG announced an immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive technology. The companies would use mRNA technology that targets tumor neoantigens for a more robust anti-cancer immune response. Thus, a rise in the prevalence of cancer coupled with the increasing efforts by the market players is anticipated to provide a significant push to segmental growth.
North America to contribute a significant share in the market
North America has enormous growth potential because of the large number of key players and the rapid increase in the number of patients in the US. In addition, increased investments and R&D efforts, a growing focus on precision medicine and novel therapeutics, a favorable regulatory environment, and an ever-increasing demand to produce transformational treatments are all contributing to the market expansion in North America. Moreover, Europe is expected to account for remarkable market growth due to a growth in clinical trials, research & development efforts, and superior technology. Furthermore, due to the development of healthcare facilities and a surge in infectious diseases, Asia-Pacific, Latin America, the Middle East & Africa are likely to experience significant growth.
Read also our latest report: https://store.rationalstat.com/store/global-clean-technology-market/
Market Structure and Competitive Landscape
The global mRNA technology market is competitive and consists of a number of global and regional players operating in the market. Pharmaceutical companies are investing in mRNA technology as it allows them to mix numerous molecules into a therapeutic drug, which is another important growth factor. The major companies in the market include Moderna Therapeutics, BioNTech, Ethris, CureVac, Argos Therapeutics, Sangamo Therapeutics Inc., Pfizer Inc, Biocon, Tiba Biotechnology, Verve Therapeutics Ltd. and many more. Diversified portfolios of leading firms in innovations and R&D activities characterize the global market, and they are likely to prioritize mergers and acquisitions, and collaborations. Recent developments observed in the market include,
- In June 2022, Pfizer Inc. announced to invest US$ 120 million in its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir tablets and ritonavir tablets).
- In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring, and painful disease. The collaboration builds on the companies’ success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.
- In October 2021, Pfizer acquired an Emergency Use Authorization (EUA) from the US FDA for the Pfizer-BioNTech COVID-19 Vaccine for children aged 5 to 11.
Key Segmentation
RationalStat has segmented the global mRNA technology market based on product, manufacturing, application, end user, and region.
- By Product
- Prophylactic Vaccines
- Therapeutic Vaccines
- Therapeutics
- By Manufacturing
- In-House
- Outsourced
- By Application
- Oncology
- Respiratory Diseases
- Infectious Diseases
- Rare Diseases
- Others (Coronary Artery Diseases etc.)
- By End User
- Hospitals and Clinics
- Academic & Research Institutions
- By Region
- North America
- US
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Western Europe
- Germany
- UK
- France
- Spain
- Italy
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Rest of Eastern Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- ASEAN (Indonesia, Vietnam, Malaysia, etc.)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- South Africa
- Turkey
- Rest of the Middle East & Africa
- North America
Research Methodology
RationalStat has developed a state-of-the-art research methodology to crunch numbers and provide the best possible real-time insights to clients. We combine a varied range of industry experience, data analytics, and experts’ viewpoint to create a research methodology for market sizing and forecasting.
RationalStat combines a mix of secondary sources as well as primary research to assess the market size and develop a forecast. Key steps involved in accurately deriving the market numbers are:
- Defining the problem by understanding the type of market and data required by the client.
- Data gathering and collection through relevant paid databases, publicly available sources, company reports, annual reports, surveys, and interviews.
- Formulating a hypothesis to create market numbers, forecasts, influencing factors, and their relevance.
- Evaluating and analyzing the data by referring to data sources utilized and leveraged.
- Validating, interpreting, and finalizing the data by combining the details gathered from primary and secondary sources with the help of experienced analysts.
Secondary Sources
- Annual reports, company filings, investor presentations, product catalogs, and company documents
- Industry and market-related documents available in the public domain
- Paid database including Bloomberg, Factiva, S&P Capital IQ, FactSet, Refinitiv Eikon, ICIS, EUWID, and Thomson Reuters, among others
- Whitepapers, research papers, and industry blogs.
Why Buy this Report?
The report is intended for healthcare & life sciences companies, pharmaceutical companies, research organizations, government organizations, educational organizations, regulatory agencies, and market research firms, among others. The report provides an in-depth analysis of market size, consumption patterns, ongoing market trends and challenges, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights to clients to find the right answers to their business questions.
Frequently Asked Questions (FAQs)
The global mRNA technology market is expected to grow at a CAGR of approximately 1.8% during the forecast period 2022-2028.
North America holds a prominent share of the global mRNA technology market.
The global market for mRNA technology was US$ 40 Billion in 2021.
The increasing prevalence of medical disorders and increased R&D investments are the major factors to influence the growth of the global mRNA technology market.
Major companies operating in the global mRNA technology market are Moderna Therapeutics, BioNTech, Ethris, CureVac, Argos Therapeutics, Sangamo Therapeutics Inc., Pfizer Inc, Biocon, Tiba Biotechnology, Verve Therapeutics Ltd. and many more.
| REGION | Global |
|---|---|
| RELEASE YEAR | 2022 |
| RESEARCH CODE | RST-SAR-079 |
| ADDITIONAL FEATURE | 24×7 Post sales support and 15% free customization |
| User License | Single User/Team License, Corporate License |
Table of Contents
1. Market Introduction
1.1. Scope of Study
1.2. Problem Statement
1.3. Market Segmentation
2. Assumptions and Acronyms
3. Executive Summary
3.1. Global Market in 2022
3.2. Analyst Insights & Recommendations
3.3. Growth Opportunities and Key Strategies
3.4. Supply-side and Demand-side Trends
4. Research Methodology
5. Analysis of COVID-19 Impact and Road Ahead
5.1. Impact on Growth Strategies
5.2. Impact on Operations and Supply Chain
5.3. Impact on Roll-outs Plans
6. Market Indicators and Background
6.1. Macro-Economic Factors
6.2. Forecasting Factors
Robust assessment of various factors including industrial performance, industry players’ expenditures, and economic conditions, among others
6.3. Supply Chain & Value Chain Analysis
6.3.1. mRNA Technology Providers
6.3.2. Key End User
6.4. Industry SWOT Analysis
6.5. PESTLE Analysis
6.6. Porter’s Five Forces Analysis
7. Rules & Regulations
8. Global and Regional Market Dynamics
8.1. Drivers
8.2. Restraints
8.3. Trends
8.4. Opportunities
9. Global mRNA Technology Industry: Key Investment and Development Analysis
9.1. By Leading Providers
9.2. By Region
9.3. By Product
9.4. By Application
9.5. M&A Activities
Robust assessment of major investments made by various industry players along with key application areas, and key regions
10. Market Spending & Use Case Analysis
11. Product/Drug Pipeline Analysis
11.1.By Key Players
11.2.By Product
11.3.By Application
11.4.By Region
12. Clinical Trials Analysis
Exhaustive list of all the clinical trials sponsored by various industry players based on the technology will be provided. Moreover, it would also categorize the trials into IND submissions, Phase I, Phase II etc.
13. Parent Market Overview: Global Healthcare & Life Sciences Market
14. Segmental Analysis
14.1.Global mRNA Technology Market by Product
14.1.1. Segment Overview
14.1.1.1. Prophylactic Vaccines
14.1.1.2. Therapeutic Vaccines
14.1.1.3. Therapeutics
14.2.Global mRNA Technology Market by Manufacturing
14.2.1. Segment Overview
14.2.1.1. In-House
14.2.1.2. Outsourced
14.3.Global mRNA Technology Market by Application
14.3.1. Segmental Overview
14.3.1.1. Oncology
14.3.1.2. Respiratory Diseases
14.3.1.3. Infectious Diseases
14.3.1.4. Rare Diseases
14.3.1.5. Others (Coronary Artery Diseases etc.)
14.4.Global mRNA Technology Market by End User
14.4.1. Segment Overview
14.4.1.1. Hospitals and Clinics
14.4.1.2. Academic & Research Institutions
14.5.Global mRNA Technology Market by Region
14.5.1. Segment Overview
14.5.1.1. North America
14.5.1.2. Latin America
14.5.1.3. Western Europe
14.5.1.4. Eastern Europe
14.5.1.5. Asia Pacific
14.5.1.6. Middle East & Africa
15. Regional Analysis
15.1.North America mRNA Technology Market Analysis and Forecast 2020-2030
15.1.1. Regional Market Overview and Key Takeaways
15.1.2. North America mRNA Technology Market by Product
15.1.3. North America mRNA Technology Market by Manufacturing
15.1.4. North America mRNA Technology Market by Application
15.1.5. North America mRNA Technology Market by End User
15.1.6. North America mRNA Technology Market by Country
15.1.6.1. US
15.1.6.2. Canada
15.2.Latin America mRNA Technology Market Analysis and Forecast 2020-2030
15.2.1. Regional Market Overview and Key Takeaways
15.2.2. Latin America mRNA Technology Market by Product
15.2.3. Latin America mRNA Technology Market by Manufacturing
15.2.4. Latin America mRNA Technology Market by Application
15.2.5. Latin America mRNA Technology Market by End User
15.2.6. Latin America mRNA Technology Market by Country
15.2.6.1. Brazil
15.2.6.2. Mexico
15.2.6.3. Rest of Latin America
15.3.Western Europe mRNA Technology Market Analysis and Forecast 2020-2030
15.3.1. Regional Market Overview and Key Takeaways
15.3.2. Western Europe mRNA Technology Market by Product
15.3.3. Western Europe mRNA Technology Market by Manufacturing
15.3.4. Western Europe mRNA Technology Market by Application
15.3.5. Western Europe mRNA Technology Market by End User
15.3.6. Western Europe mRNA Technology Market by Country
15.3.6.1. Germany
15.3.6.2. UK
15.3.6.3. France
15.3.6.4. Spain
15.3.6.5. Italy
15.3.6.6. Benelux
15.3.6.7. Nordic
15.3.6.8. Rest of Western Europe
15.4.Eastern Europe mRNA Technology Market Analysis and Forecast 2020-2030
15.4.1. Regional Market Overview and Key Takeaways
15.4.2. Eastern Europe mRNA Technology Market by Product
15.4.3. Eastern Europe mRNA Technology Market by Manufacturing
15.4.4. Eastern Europe mRNA Technology Market by Application
15.4.5. Eastern Europe mRNA Technology Market by End User
15.4.6. Eastern Europe mRNA Technology Market by Country
15.4.6.1. Russia
15.4.6.2. Poland
15.4.6.3. Rest of Eastern Europe
15.5.Asia Pacific mRNA Technology Market Analysis and Forecast 2020-2030
15.5.1. Regional Market Overview and Key Takeaways
15.5.2. Asia Pacific mRNA Technology Market by Product
15.5.3. Asia Pacific mRNA Technology Market by Manufacturing
15.5.4. Asia Pacific mRNA Technology Market by Application
15.5.5. Asia Pacific mRNA Technology Market by End User
15.5.6. Asia Pacific mRNA Technology Market by Country
15.5.6.1. China
15.5.6.2. Japan
15.5.6.3. India
15.5.6.4. South Korea
15.5.6.5. Australia
15.5.6.6. ASEAN
15.5.6.7. Rest of Asia-Pacific
15.6.Middle East & Africa mRNA Technology Market Analysis and Forecast 2020-2030
15.6.1. Regional Market Overview and Key Takeaways
15.6.2. Middle East & Africa mRNA Technology Market by Product
15.6.3. Middle East & Africa mRNA Technology Market by Manufacturing
15.6.4. Middle East & Africa mRNA Technology Market by Application
15.6.5. Middle East & Africa mRNA Technology Market by End User
15.6.6. Middle East & Africa mRNA Technology Market by Country
15.6.6.1. GCC
15.6.6.2. South Africa
15.6.6.3. Turkey
15.6.6.4. Rest of the Middle East & Africa
16. Competitive Landscape
16.1.Competition Dashboard
16.1.1. Global and Regional Market Share Analysis
16.1.2. Market Structure
16.2.Competitive Benchmarking
16.3.Key Strategy Analysis
16.4.Company Profiles
16.4.1. Moderna Therapeutics
16.4.1.1. Company Overview
16.4.1.2. Product/Service Offerings
16.4.1.3. Key Financials
16.4.1.4. Recent Developments
16.4.2. BioNTech SE
16.4.2.1. Company Overview
16.4.2.2. Product/Service Offerings
16.4.2.3. Key Financials
16.4.2.4. Recent Developments
16.4.3. Ethris GmbH
16.4.3.1. Company Overview
16.4.3.2. Product/Service Offerings
16.4.3.3. Key Financials
16.4.3.4. Recent Developments
16.4.4. AstraZeneca Plc
16.4.4.1. Company Overview
16.4.4.2. Product/Service Offerings
16.4.4.3. Financials
16.4.4.4. Recent Developments
16.4.5. CureVac AG
16.4.5.1. Company Overview
16.4.5.2. Product/Service Offerings
16.4.5.3. Financials
16.4.5.4. Recent Developments
16.4.6. Argos Therapeutics, Inc.
16.4.6.1. Company Overview
16.4.6.2. Product/Service Offerings
16.4.6.3. Financials
16.4.6.4. Recent Developments
16.4.7. Sangamo Therapeutics Inc.
16.4.7.1. Company Overview
16.4.7.2. Product/Service Offerings
16.4.7.3. Financials
16.4.7.4. Recent Developments
16.4.8. Pfizer Inc.
16.4.8.1. Company Overview
16.4.8.2. Product/Service Offerings
16.4.8.3. Financials
16.4.8.4. Recent Developments
16.4.9. Biocon Ltd.
16.4.9.1. Company Overview
16.4.9.2. Product/Service Offerings
16.4.9.3. Financials
16.4.9.4. Recent Developments
16.4.10. Tiba Biotechnology
16.4.10.1. Company Overview
16.4.10.2. Product/Service Offerings
16.4.10.3. Financials
16.4.10.4. Recent Developments
16.4.11. Verve Therapeutics Inc.
16.4.11.1. Company Overview
16.4.11.2. Product/Service Offerings
16.4.11.3. Financials
16.4.11.4. Recent Developments
16.4.12. Takeda Pharmaceutical Co, Ltd.
16.4.12.1. Company Overview
16.4.12.2. Product/Service Offerings
16.4.12.3. Financials
16.4.12.4. Recent Developments
16.4.13. Intellia Therapeutics Inc.
16.4.13.1. Company Overview
16.4.13.2. Product/Service Offerings
16.4.13.3. Financials
16.4.13.4. Recent Developments
16.4.14. Kernal Biologics Inc.
16.4.14.1. Company Overview
16.4.14.2. Product/Service Offerings
16.4.14.3. Financials
16.4.14.4. Recent Developments
*List not exhaustive (Players can be added or replaced as per the customization)
17. Disclaimer
Every Sample Includes
Research Methodology
Complete Table of Contents, List of Charts and Tables
Exclusive Facts & Illustrations
Related products
Healthcare & Pharmaceutical
Global Dialysis Concentrate Market Analysis & Forecast 2019-2028
Global market growth is being driven by an increase in dialysis patient mortality
Healthcare & Pharmaceutical
Global AI in Drug Discovery Market Analysis and Forecast, 2022-2028
The global AI in the Drug Discovery market was US$ 780 million in 2021 and is expected to grow at a CAGR of 26.8% over the forecast period of 2023-2028.
Healthcare & Pharmaceutical
Global Pharmaceutical Sterility Testing Market Analysis and Forecast 2019-2028
Growth in the pharmaceuticals and biotechnology industry driving the pharmaceutical sterility testing market
Healthcare & Pharmaceutical
Global Healthcare Information System (HIS) Market Analysis and Forecast 2019-2028
Increasing adoption of IT solutions in healthcare facilities to enhance efficiency is fueling the market growth
Healthcare & Pharmaceutical
Global Advanced Wound Care Market Analysis and Forecast, 2023-2030
Market Introduction: Key Takeaways The global advanced wound care market was valued at US$ 9.87 billion in 2022 and is expected to grow at a CAGR of 6.2% from 2023 to 2028. The market is being driven by an increasing incidence of chronic diseases such as diabetes, obesity, and cancer, which often lead to chronic [...]
Healthcare & Pharmaceutical
Global Clinical Diagnostics Market Analysis and Forecast 2019-2028
The increasing healthcare spending and technological advancements are expected to drive the market revenue